Literature DB >> 8675673

A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease.

M Serrato1, A J Marian.   

Abstract

Coronary artery disease (CAD) is a complex trait caused by a number of genetic and environmental factors. Recently, paraoxonase/arylesterase (PONA) enzyme has been implicated in the pathogenesis of atherosclerosis. There is a 10-40-fold variability in the activity of this enzyme among individuals. This variability is due to the presence of an A/G polymorphism in the coding region of the gene (HUMPONA). The A and G alleles code for glutamine (A genotype) and arginine (B genotype), respectively. Individuals with A genotype have a lower enzymatic activity than those with B genotype. We determined the HUMPONA genotypes and alleles in 223 patients with angiographically documented CAD and in 247 individuals in the general population. The distribution of genotypes were in Hardy-Weinberg equilibrium in patients and in controls. Genotypes A and B were present in 120 (49%) and 28 (11%) individuals in controls and in 68 (30%) and 40 (18%) patients with CAD, respectively (chi squared= 16.5, P= 0.0003). The frequency of the A allele was 0.69 in controls and 0.56 in patients (OR= 1.7, P= 0.0001). There were no differences in the distribution of HUMPONA genotypes in the subgroups of patients with restenosis, myocardial infarction, or any of the conventional risk factors for CAD as compared with corresponding subgroups. In summary, variants of the HUMPONA gene are involved in predisposition to coronary atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8675673      PMCID: PMC186013          DOI: 10.1172/JCI118373

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

Review 1.  Genetic susceptibility to atherosclerosis.

Authors:  J C Chamberlain; D J Galton
Journal:  Br Med Bull       Date:  1990-10       Impact factor: 4.291

2.  Effects of LDL apheresis on restenosis after angioplasty.

Authors:  S Kanemitsu; N Tekekoshi; E Murakami
Journal:  Chem Phys Lipids       Date:  1994-01       Impact factor: 3.329

Review 3.  Is paraoxonase related to atherosclerosis.

Authors:  M I Mackness; S Arrol; C A Abbott; P N Durrington
Journal:  Chem Biol Interact       Date:  1993-06       Impact factor: 5.192

Review 4.  Genetic dissection of complex traits.

Authors:  E S Lander; N J Schork
Journal:  Science       Date:  1994-09-30       Impact factor: 47.728

Review 5.  Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification.

Authors:  C E Furlong; L G Costa; C Hassett; R J Richter; J A Sundstrom; D A Adler; C M Disteche; C J Omiecinski; C Chapline; J W Crabb
Journal:  Chem Biol Interact       Date:  1993-06       Impact factor: 5.192

6.  The molecular basis of the human serum paraoxonase activity polymorphism.

Authors:  R Humbert; D A Adler; C M Disteche; C Hassett; C J Omiecinski; C E Furlong
Journal:  Nat Genet       Date:  1993-01       Impact factor: 38.330

7.  Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein.

Authors:  M I Mackness; S Arrol; P N Durrington
Journal:  FEBS Lett       Date:  1991-07-29       Impact factor: 4.124

8.  Apolipoprotein polymorphisms fail to define risk of coronary artery disease. Results of a prospective, angiographically controlled study.

Authors:  H W Marshall; L C Morrison; L L Wu; J L Anderson; P S Corneli; D M Stauffer; A Allen; L A Karagounis; R H Ward
Journal:  Circulation       Date:  1994-02       Impact factor: 29.690

9.  Genetic susceptibility to death from coronary heart disease in a study of twins.

Authors:  M E Marenberg; N Risch; L F Berkman; B Floderus; U de Faire
Journal:  N Engl J Med       Date:  1994-04-14       Impact factor: 91.245

10.  Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes.

Authors:  S Adkins; K N Gan; M Mody; B N La Du
Journal:  Am J Hum Genet       Date:  1993-03       Impact factor: 11.025

View more
  42 in total

1.  A multilocus genotyping assay for candidate markers of cardiovascular disease risk.

Authors:  S Cheng; M A Grow; C Pallaud; W Klitz; H A Erlich; S Visvikis; J J Chen; C R Pullinger; M J Malloy; G Siest; J P Kane
Journal:  Genome Res       Date:  1999-10       Impact factor: 9.043

2.  Relationship between Paraoxonase 1 (PON1) gene polymorphisms and susceptibility of stroke: a meta-analysis.

Authors:  Indranil Banerjee
Journal:  Eur J Epidemiol       Date:  2010-06-09       Impact factor: 8.082

3.  Variants associated with common disease are not unusually differentiated in frequency across populations.

Authors:  Kirk E Lohmueller; Matthew M Mauney; David Reich; John M Braverman
Journal:  Am J Hum Genet       Date:  2005-11-16       Impact factor: 11.025

4.  Immunobiochemical analysis of Paraoxonase1 (anti-oxidant), xanthine oxidase (oxidant) enzymes and lipid profile of cardiac disease patients in Lahore Metropolitan, Pakistan.

Authors:  Zahoor Qadir Samra; Adeela Sana; Sadia Bano; Mariam Farooq; Nadia Dar; Muhammad Amin Athar
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

5.  Single-tube genotyping without oligonucleotide probes.

Authors:  S Germer; R Higuchi
Journal:  Genome Res       Date:  1999-01       Impact factor: 9.043

6.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes.

Authors:  M C Garin; R W James; P Dussoix; H Blanché; P Passa; P Froguel; J Ruiz
Journal:  J Clin Invest       Date:  1997-01-01       Impact factor: 14.808

7.  Interaction of folate intake and the paraoxonase Q192R polymorphism with risk of incident coronary heart disease and ischemic stroke: the atherosclerosis risk in communities study.

Authors:  Hung N Luu; Pascal L Kingah; Kari North; Eric Boerwinkle; Kelly A Volcik
Journal:  Ann Epidemiol       Date:  2011-11       Impact factor: 3.797

8.  Oxidative stress and nephrolithiasis: a comparative pilot study evaluating the effect of pomegranate extract on stone risk factors and elevated oxidative stress levels of recurrent stone formers and controls.

Authors:  Chad R Tracy; Jonathan R Henning; Mark R Newton; Michael Aviram; M Bridget Zimmerman
Journal:  Urolithiasis       Date:  2014-08-02       Impact factor: 3.436

9.  Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio.

Authors:  M Navab; S Hama-Levy; B J Van Lenten; G C Fonarow; C J Cardinez; L W Castellani; M L Brennan; A J Lusis; A M Fogelman; B N La Du
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

10.  Association between paraoxonase-1 activity and lipid peroxidation indicator levels in people living in the Antalya region with angiographically documented coronary artery disease.

Authors:  Ayşe Yeşim Göçmen; Saadet Gümüşlü; Ender Semiz
Journal:  Clin Cardiol       Date:  2004-07       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.